HRP20260358T1 - Spoj agonist thr-beta receptora i postupak za njegovu proizvodnju kao i njegova uporaba - Google Patents
Spoj agonist thr-beta receptora i postupak za njegovu proizvodnju kao i njegova uporabaInfo
- Publication number
- HRP20260358T1 HRP20260358T1 HRP20260358TT HRP20260358T HRP20260358T1 HR P20260358 T1 HRP20260358 T1 HR P20260358T1 HR P20260358T T HRP20260358T T HR P20260358TT HR P20260358 T HRP20260358 T HR P20260358T HR P20260358 T1 HRP20260358 T1 HR P20260358T1
- Authority
- HR
- Croatia
- Prior art keywords
- thr
- procedure
- production
- well
- receptor agonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811527414.4A CN111320609A (zh) | 2018-12-13 | 2018-12-13 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| EP19896475.1A EP3893889B8 (en) | 2018-12-13 | 2019-12-12 | Thrb receptor agonist compound and preparation method and use thereof |
| PCT/US2019/066013 WO2020123827A1 (en) | 2018-12-13 | 2019-12-12 | Thrβ receptor agonist compound and preparation method and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20260358T1 true HRP20260358T1 (hr) | 2026-04-24 |
Family
ID=71071432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20260358TT HRP20260358T1 (hr) | 2018-12-13 | 2019-12-12 | Spoj agonist thr-beta receptora i postupak za njegovu proizvodnju kao i njegova uporaba |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US11084802B2 (https=) |
| EP (3) | EP3893889B8 (https=) |
| JP (3) | JP7532371B2 (https=) |
| KR (2) | KR102905557B1 (https=) |
| CN (4) | CN111320609A (https=) |
| AR (1) | AR117694A1 (https=) |
| AU (2) | AU2019398339C1 (https=) |
| BR (1) | BR112021010871A2 (https=) |
| CA (1) | CA3120880A1 (https=) |
| CL (1) | CL2021001521A1 (https=) |
| CO (1) | CO2021008817A2 (https=) |
| DK (2) | DK4574821T3 (https=) |
| ES (1) | ES3064255T3 (https=) |
| FI (2) | FI4574821T3 (https=) |
| HR (1) | HRP20260358T1 (https=) |
| IL (3) | IL310699B2 (https=) |
| LT (2) | LT4574821T (https=) |
| MA (1) | MA54471A (https=) |
| MX (2) | MX2021006908A (https=) |
| MY (1) | MY207657A (https=) |
| PE (2) | PE20252338A1 (https=) |
| PT (1) | PT3893889T (https=) |
| SG (1) | SG11202106194TA (https=) |
| TW (3) | TW202600541A (https=) |
| WO (1) | WO2020123827A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR092872A1 (es) | 2012-09-17 | 2015-05-06 | Madrigal Pharmaceuticals Inc | Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos |
| ES3029158T3 (en) | 2018-06-12 | 2025-06-23 | Xizang Haisco Pharmaceutical Co Ltd | Thyroid hormone receptor agonists and uses thereof |
| TWI884745B (zh) | 2018-10-12 | 2025-05-21 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| KR20220017917A (ko) | 2019-05-08 | 2022-02-14 | 알리고스 테라퓨틱스 인코포레이티드 | Thr-베타의 조절제 및 이의 사용 방법 |
| WO2020228577A1 (zh) * | 2019-05-10 | 2020-11-19 | 深圳微芯生物科技股份有限公司 | 一种哒嗪酮衍生物及其应用 |
| WO2020239076A1 (zh) * | 2019-05-29 | 2020-12-03 | 南京明德新药研发有限公司 | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 |
| AU2020336272A1 (en) | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021050945A1 (en) | 2019-09-12 | 2021-03-18 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| TW202128668A (zh) * | 2019-12-16 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 并環類衍生物、其製備方法及其在醫藥上的應用 |
| US20210379043A1 (en) * | 2020-05-13 | 2021-12-09 | Terns Pharmaceuticals, Inc. | Combination treatment of liver disorders |
| CA3193057A1 (en) | 2020-08-25 | 2022-03-03 | Eli Lilly And Company | Polymorphs of an ssao inhibitor |
| WO2022053028A1 (zh) * | 2020-09-10 | 2022-03-17 | 南京明德新药研发有限公司 | 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用 |
| CA3192169A1 (en) * | 2020-09-17 | 2022-03-24 | Sunshine Lake Pharma Co., Ltd. | A compound as a thyroid hormone beta receptor agonist and use thereof |
| CA3195960A1 (en) * | 2020-10-23 | 2022-04-28 | Madrigal Pharmaceuticals, Inc. | Process for the preparation of 6-(4-nitro-phenoxy)-2h-pyridazin-3-one and 6-(4-amino-phenoxy)-2h-pyridazin-3-one derivatives as intermediates of thyroid hormone analogues |
| AU2021374988A1 (en) * | 2020-11-06 | 2023-06-15 | Aligos Therapeutics, Inc. | Bicyclic pyridazinones as thyroid hormone receptor beta (tr-beta) agonists |
| CN114437034A (zh) * | 2020-11-06 | 2022-05-06 | 深圳微芯生物科技股份有限公司 | 一种酞嗪类化合物的可药用盐、晶型及其制备方法 |
| CN114591300A (zh) * | 2020-12-04 | 2022-06-07 | 南京圣和药业股份有限公司 | 作为THRβ激动剂的杂环化合物及其应用 |
| CN114634486B (zh) * | 2020-12-15 | 2024-01-30 | 中国科学院上海药物研究所 | 甲状腺素受体β 选择性激动剂化合物、其药物组合物和用途 |
| CN114685450A (zh) | 2020-12-30 | 2022-07-01 | 昆药集团股份有限公司 | 2-吡啶酮类衍生物及其制备方法和在医药上的应用 |
| PE20240097A1 (es) * | 2021-03-03 | 2024-01-18 | Terns Pharmaceuticals Inc | Compuestos agonistas beta del receptor de la hormona tiroidea |
| PE20241327A1 (es) * | 2021-11-11 | 2024-06-26 | Terns Pharmaceuticals Inc | Tratamiento de trastornos hepaticos con un agonista del thr-beta |
| CN119013027A (zh) | 2021-11-11 | 2024-11-22 | 拓臻制药公司 | 用于治疗肝脏病症的SSAO抑制剂和THR-β激动剂的组合 |
| CA3252274A1 (en) * | 2022-02-10 | 2023-08-17 | Madrigal Pharmaceuticals, Inc. | THR BETA ANALOGUES AND THEIR USES |
| CN118146217A (zh) | 2022-12-07 | 2024-06-07 | 昆药集团股份有限公司 | 一种甲状腺激素β受体激动剂、晶型、制备方法和用途 |
| JPWO2024143235A1 (https=) * | 2022-12-26 | 2024-07-04 | ||
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| WO2025162405A1 (zh) * | 2024-02-01 | 2025-08-07 | 罗群 | 苯酚类衍生物及其医药用途 |
| US12377104B1 (en) | 2024-02-06 | 2025-08-05 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025245216A1 (en) * | 2024-05-22 | 2025-11-27 | Terns Pharmaceuticals, Inc. | Treatment of liver disorders with a thr-beta agonist |
| US20260102403A1 (en) * | 2024-10-11 | 2026-04-16 | Aligos Therapeutics, Inc. | Oral formulations of thr-beta agonist |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4197307A (en) | 1977-04-12 | 1980-04-08 | Ciba-Geigy Corporation | 2-Alkylthio-, 2-alkylsulphinyl- and 2-alkylsulfonyl-6-phenylbenzimidazoles as anthelmintic agents |
| EP0377903A3 (de) | 1989-01-09 | 1991-07-17 | Bayer Ag | Substituierte Hexahydro-1,2,4-triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung |
| ES2240017T3 (es) | 1999-09-30 | 2005-10-16 | Pfizer Products Inc. | Derivados de 6-azauracilo como ligandos de receptores tiroideos. |
| US6787652B1 (en) | 1999-09-30 | 2004-09-07 | Pfizer, Inc. | 6-Azauracil derivatives as thyroid receptor ligands |
| GB0015205D0 (en) | 2000-06-21 | 2000-08-09 | Karobio Ab | Bioisosteric thyroid receptor ligands and method |
| EP1347959A1 (de) | 2000-12-27 | 2003-10-01 | Bayer Aktiengesellschaft | Indol-derivate |
| EP1471049A4 (en) * | 2002-01-30 | 2006-08-16 | Kissei Pharmaceutical | NEW THYROIDIAN HORMONE RECEPTOR LIGAND, MEDICINAL PREPARATIONS CONTAINING THE SAME AND USE THEREOF |
| WO2003094845A2 (en) | 2002-05-08 | 2003-11-20 | Bristol-Myers Squibb Company | Pyridine-based thyroid receptor ligands |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| FR2882750B1 (fr) | 2005-03-03 | 2007-05-11 | Pierre Fabre Medicament Sa | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
| GB0513692D0 (en) | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
| DK1919878T3 (da) * | 2005-07-21 | 2010-10-25 | Hoffmann La Roche | Pyridazinonderivater som thyroidhormonreceptoragonister |
| GB0608724D0 (en) | 2006-05-03 | 2006-06-14 | Karobio Ab | Novel Pharmaceutical Compositions |
| GB0610322D0 (en) | 2006-05-24 | 2006-07-05 | Karobio Ab | Novel pharmaceutical compositions |
| WO2008130637A1 (en) | 2007-04-18 | 2008-10-30 | New York University | Hydrazide compounds as thyroid hormone receptor modulators and uses thereof |
| WO2009001359A2 (en) | 2007-06-27 | 2008-12-31 | Quark Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of pro-apoptotic genes |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| US8076334B2 (en) | 2007-09-20 | 2011-12-13 | Hoffmann-La Roche Inc. | Prodrugs of thyroid hormone analogs |
| FR2933979B1 (fr) | 2008-07-15 | 2012-08-24 | Pf Medicament | Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine |
| RU2527948C2 (ru) | 2009-04-20 | 2014-09-10 | Мицубиси Танабе Фарма Корпорейшн | Новый агонист бета рецептора тиреоидного гормона |
| WO2011038207A1 (en) | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| JP2011114768A (ja) | 2009-11-30 | 2011-06-09 | Panasonic Corp | 複合無線装置 |
| SG11201402004YA (en) | 2011-11-14 | 2014-05-29 | Cephalon Inc | Uracil derivatives as axl and c-met kinase inhibitors |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| CN102898377B (zh) * | 2012-02-14 | 2016-01-20 | 南京圣和药业股份有限公司 | 一类酞嗪酮衍生物及其用途 |
| AR092872A1 (es) | 2012-09-17 | 2015-05-06 | Madrigal Pharmaceuticals Inc | Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos |
| KR102374499B1 (ko) | 2014-04-11 | 2022-03-14 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | Nafld 및 nash 의 치료 |
| CN107074823B (zh) | 2014-09-05 | 2021-05-04 | 基因泰克公司 | 治疗性化合物及其用途 |
| CN105477636B (zh) | 2015-10-16 | 2019-09-17 | 厦门大学 | 使用阿维菌素及其衍生物治疗代谢疾病的方法 |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US11419878B2 (en) | 2016-03-28 | 2022-08-23 | Intercept Pharmaceuticals, Inc. | Medicine obtained by combining FXR agonist and ARB |
| SMT202500241T1 (it) | 2016-03-31 | 2025-07-22 | Genfit | Elafibranor per uso nel trattamento di colangite biliare primitiva |
| BR112018073460A2 (pt) | 2016-05-25 | 2019-07-09 | Akarna Therapeutics Ltd | terapias combinadas usando moduladores do receptor farnesoide x (fxr) |
| WO2018027892A1 (en) | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
| WO2018075650A1 (en) | 2016-10-18 | 2018-04-26 | Madrigal Pharmaceuticals, Inc. | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
| US20210212968A1 (en) | 2016-10-19 | 2021-07-15 | Boehringer Ingelheim International Gmbh | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof |
| WO2018103624A1 (zh) | 2016-12-06 | 2018-06-14 | 江苏恒瑞医药股份有限公司 | 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途 |
| KR102314286B1 (ko) | 2016-12-16 | 2021-10-21 | 화이자 인코포레이티드 | Glp-1 수용체 작용제 및 이의 용도 |
| JP7618384B2 (ja) | 2017-02-21 | 2025-01-21 | ジェンフィ | Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ |
| WO2018167103A1 (en) | 2017-03-13 | 2018-09-20 | Genfit | Pharmaceutical compositions for combination therapy |
| WO2018170173A1 (en) | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| JP7266531B2 (ja) | 2017-04-18 | 2023-04-28 | ジェンフィ | エラフィブラノール又はその誘導体と抗ｎａｓｈ剤、抗線維化剤又は抗胆汁うっ滞性剤の組合せ |
| WO2018208707A1 (en) | 2017-05-08 | 2018-11-15 | Neurovia, Inc. | Methods and compositions for treating demyelinating diseases |
| US20210121493A1 (en) | 2017-07-25 | 2021-04-29 | Cedars-Sinai Medical Center | Methods for treating liver diseases |
| CN111032884A (zh) | 2017-08-25 | 2020-04-17 | 基恩菲特公司 | 非酒精性脂肪性肝病、非酒精性脂肪性肝炎和/或肝纤维化的非侵入性诊断 |
| WO2019053235A1 (en) | 2017-09-15 | 2019-03-21 | Genfit | NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS |
| EP3684954B1 (en) | 2017-09-18 | 2025-11-26 | Genfit | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis |
| JP7264906B2 (ja) | 2017-11-01 | 2023-04-25 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレーターとしてのアルケン化合物 |
| EP3710599B1 (en) | 2017-11-13 | 2024-07-17 | Gilead Sciences, Inc. | Method for staging liver fibrosis in nash patients |
| JP7156722B2 (ja) | 2018-01-23 | 2022-10-19 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | 置換ピリダジノン化合物 |
| WO2019209738A1 (en) | 2018-04-24 | 2019-10-31 | Ph Pharma Co., Ltd. | Use of neutrophil elastase inhibitors in liver disease |
| ES3029158T3 (en) | 2018-06-12 | 2025-06-23 | Xizang Haisco Pharmaceutical Co Ltd | Thyroid hormone receptor agonists and uses thereof |
| CN112805005A (zh) | 2018-08-24 | 2021-05-14 | 拓臻股份有限公司 | 甲状腺素受体β促效剂化合物 |
| US11541745B2 (en) | 2018-08-24 | 2023-01-03 | Plastic Omnium Advanced Innovation And Research | Assembly for a fluid tank comprising a baffle and a fluid transfer line passing through the baffle |
| EP3844156A4 (en) | 2018-08-30 | 2022-06-08 | Terns Pharmaceuticals, Inc. | TREATMENT OF HEPATIC DISORDERS |
| NZ773110A (en) | 2018-09-18 | 2024-11-29 | Terns Inc | Compounds for treating certain leukemias |
| EA202190661A1 (ru) | 2018-09-18 | 2021-08-13 | Метакрайн, Инк. | Агонисты фарнезоидного х-рецептора для лечения заболевания |
| CA3113373A1 (en) | 2018-10-12 | 2020-04-16 | InventisBio Co., Ltd. | Thyroid hormone receptor agonists |
| TWI884745B (zh) | 2018-10-12 | 2025-05-21 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| EP3897666A2 (en) | 2018-12-17 | 2021-10-27 | Mitopower LLC | Nicotinyl riboside compounds and their uses |
| CN111484481A (zh) | 2019-01-26 | 2020-08-04 | 察略盛医药科技(上海)有限公司 | 哒嗪酮类衍生物、其制备方法及其在医药上的用途 |
| CN113474335B (zh) | 2019-02-21 | 2024-12-03 | 南京瑞捷医药科技有限公司 | 化合物及其作为甲状腺激素受体激动剂的用途 |
| KR20220017917A (ko) | 2019-05-08 | 2022-02-14 | 알리고스 테라퓨틱스 인코포레이티드 | Thr-베타의 조절제 및 이의 사용 방법 |
| WO2020228577A1 (zh) | 2019-05-10 | 2020-11-19 | 深圳微芯生物科技股份有限公司 | 一种哒嗪酮衍生物及其应用 |
| WO2020239076A1 (zh) | 2019-05-29 | 2020-12-03 | 南京明德新药研发有限公司 | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 |
| EP4003349A1 (en) | 2019-07-23 | 2022-06-01 | Novartis AG | Combination treatment of liver diseases using fxr agonists |
| CN112409340B (zh) | 2019-08-21 | 2022-03-18 | 海创药业股份有限公司 | 卤素取代的苯醚类化合物及其用途 |
| AU2020336272A1 (en) | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021050945A1 (en) | 2019-09-12 | 2021-03-18 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| TW202128668A (zh) | 2019-12-16 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 并環類衍生物、其製備方法及其在醫藥上的應用 |
| US20210379043A1 (en) | 2020-05-13 | 2021-12-09 | Terns Pharmaceuticals, Inc. | Combination treatment of liver disorders |
| US20210379040A1 (en) | 2020-05-13 | 2021-12-09 | Terns Pharmaceuticals, Inc. | Combination treatment of liver disorders |
| AU2021359895A1 (en) | 2020-10-15 | 2023-06-15 | Eli Lilly And Company | Polymorphs of an fxr agonist |
| CN114437034A (zh) | 2020-11-06 | 2022-05-06 | 深圳微芯生物科技股份有限公司 | 一种酞嗪类化合物的可药用盐、晶型及其制备方法 |
| KR20230154806A (ko) | 2021-01-14 | 2023-11-09 | 엔요 파마 | Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과 |
| PE20240097A1 (es) | 2021-03-03 | 2024-01-18 | Terns Pharmaceuticals Inc | Compuestos agonistas beta del receptor de la hormona tiroidea |
| WO2022194278A1 (zh) | 2021-03-19 | 2022-09-22 | 南京明德新药研发有限公司 | 双环苯酚类化合物及其应用 |
| CN119013027A (zh) | 2021-11-11 | 2024-11-22 | 拓臻制药公司 | 用于治疗肝脏病症的SSAO抑制剂和THR-β激动剂的组合 |
| PE20241327A1 (es) | 2021-11-11 | 2024-06-26 | Terns Pharmaceuticals Inc | Tratamiento de trastornos hepaticos con un agonista del thr-beta |
| WO2023220404A1 (en) | 2022-05-13 | 2023-11-16 | Terns Pharmaceuticals, Inc. | Treatment of non-alcoholic steatohepatitis |
-
2018
- 2018-12-13 CN CN201811527414.4A patent/CN111320609A/zh active Pending
- 2018-12-13 CN CN202511225496.7A patent/CN121081472A/zh active Pending
-
2019
- 2019-12-12 MX MX2021006908A patent/MX2021006908A/es unknown
- 2019-12-12 FI FIEP25157448.9T patent/FI4574821T3/fi active
- 2019-12-12 MA MA054471A patent/MA54471A/fr unknown
- 2019-12-12 EP EP19896475.1A patent/EP3893889B8/en active Active
- 2019-12-12 PE PE2025001790A patent/PE20252338A1/es unknown
- 2019-12-12 BR BR112021010871-8A patent/BR112021010871A2/pt unknown
- 2019-12-12 US US16/712,301 patent/US11084802B2/en active Active
- 2019-12-12 WO PCT/US2019/066013 patent/WO2020123827A1/en not_active Ceased
- 2019-12-12 DK DK25157448.9T patent/DK4574821T3/da active
- 2019-12-12 CN CN201980081797.3A patent/CN113194958B/zh active Active
- 2019-12-12 ES ES19896475T patent/ES3064255T3/es active Active
- 2019-12-12 IL IL310699A patent/IL310699B2/en unknown
- 2019-12-12 PE PE2021000858A patent/PE20211788A1/es unknown
- 2019-12-12 PT PT198964751T patent/PT3893889T/pt unknown
- 2019-12-12 TW TW114133235A patent/TW202600541A/zh unknown
- 2019-12-12 AU AU2019398339A patent/AU2019398339C1/en active Active
- 2019-12-12 TW TW108145594A patent/TWI837244B/zh active
- 2019-12-12 AR ARP190103650A patent/AR117694A1/es unknown
- 2019-12-12 CA CA3120880A patent/CA3120880A1/en active Pending
- 2019-12-12 CN CN202310453989.0A patent/CN116444498B/zh active Active
- 2019-12-12 SG SG11202106194TA patent/SG11202106194TA/en unknown
- 2019-12-12 JP JP2021533640A patent/JP7532371B2/ja active Active
- 2019-12-12 FI FIEP19896475.1T patent/FI3893889T3/fi active
- 2019-12-12 TW TW113107718A patent/TWI899867B/zh active
- 2019-12-12 LT LTEP25157448.9T patent/LT4574821T/lt unknown
- 2019-12-12 IL IL283362A patent/IL283362B2/en unknown
- 2019-12-12 KR KR1020217021249A patent/KR102905557B1/ko active Active
- 2019-12-12 MY MYPI2021002740A patent/MY207657A/en unknown
- 2019-12-12 EP EP25157450.5A patent/EP4529954A3/en active Pending
- 2019-12-12 DK DK19896475.1T patent/DK3893889T3/da active
- 2019-12-12 KR KR1020257028884A patent/KR20250133486A/ko active Pending
- 2019-12-12 HR HRP20260358TT patent/HRP20260358T1/hr unknown
- 2019-12-12 EP EP25157448.9A patent/EP4574821B8/en active Active
- 2019-12-12 LT LTEPPCT/US2019/066013T patent/LT3893889T/lt unknown
-
2020
- 2020-09-04 US US17/013,314 patent/US11034676B2/en active Active
-
2021
- 2021-06-10 CL CL2021001521A patent/CL2021001521A1/es unknown
- 2021-06-10 MX MX2024003295A patent/MX2024003295A/es unknown
- 2021-07-02 CO CONC2021/0008817A patent/CO2021008817A2/es unknown
-
2023
- 2023-05-10 US US18/315,291 patent/US12338232B2/en active Active
-
2024
- 2024-07-31 JP JP2024124269A patent/JP2024174860A/ja active Pending
-
2025
- 2025-02-13 US US19/052,557 patent/US12459926B2/en active Active
- 2025-02-13 US US19/052,553 patent/US12365669B2/en active Active
- 2025-03-05 AU AU2025201590A patent/AU2025201590A1/en active Pending
- 2025-09-04 US US19/319,446 patent/US20260001867A1/en active Pending
- 2025-11-06 IL IL324507A patent/IL324507A/en unknown
- 2025-12-04 JP JP2025229427A patent/JP2026035823A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20260358T1 (hr) | Spoj agonist thr-beta receptora i postupak za njegovu proizvodnju kao i njegova uporaba | |
| EP4069686A4 (en) | GPP-1 RECEPTOR AGONISTS | |
| DK3810201T3 (da) | GIP/GLP1-agonist-sammensætninger | |
| EP3849598A4 (en) | Anti-trem-2 agonist antibodies | |
| DK3762380T3 (da) | Phenylpyrrolidinon-formylpeptid-2-receptoragonister | |
| PL3660004T3 (pl) | Związki i sposoby do ukierunkowanej degradacji receptora androgenowego | |
| DK3517538T3 (da) | Pyrazolopyridin-derivat med GLP-1-receptoragonistvirkning | |
| EP3650449A4 (en) | FXR RECEPTOR AGONIST | |
| IL249698A0 (en) | Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors | |
| EP3344295A4 (en) | CHIMERIC ANTI-SIALYL TN ANTIGEN RECEPTORS | |
| LT3684813T (lt) | Agonistiniai cd40 antikūnai | |
| ZA201804943B (en) | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar | |
| LT3713928T (lt) | Nauji bradikinino b2 receptoriaus antagonistai | |
| DK3104847T3 (da) | Hidtil ukendt anvendelse af sigma-1-receptoragonistforbindelser | |
| DK3823970T3 (da) | Yderligere substituerede triazoloquinoxalinderivater | |
| IL280199A (en) | Receptor for vista | |
| EP3875451A4 (en) | TLR8 AGONIST | |
| EP3854794A4 (en) | Tlr8 agonist | |
| EP3720445A4 (en) | SELECTIVE BETA-2 ADRENERGIC RECEPTOR AGONISTS | |
| LT3618821T (lt) | Nefrogeninio necukrinio diabeto valdymas | |
| MA46464A (fr) | Polymorphes de l'agoniste de récepteur muscarinique | |
| EP3750879A4 (en) | PROSTACYCLINE RECEPTOR AGONIST | |
| LT3806859T (lt) | Gydymo histamino-3 receptorių atvirkštiniu agonistu būdas | |
| PL3947360T3 (pl) | Związki hamujące receptor serotoninowy 5-HT2B | |
| EP3649132A4 (en) | A PERIPHERALLY-RESTRICTED DUAL-ACTINGKAPPA |